Cytokine Signalling Forum

Publications




Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials

Solipuram V, Mohan A, Patel R, Ni R. - Auto Immun Highlights. 2021;12(1):8.

The combination of JAK inhibitors with MTX is not associated with an increased risk of malignancy when compared to MTX alone. Although long-term studies are needed to confirm this conclusion from short-term studies.

Although it is now known that patients with RA are predisposed to an increased risk of malignancy, especially malignant lymphomas, lung cancers and non-melanoma skin cancer, it remains unclear whether the combination therapy is associated with a higher risk.

To this end, Solipuram, et al. used a systematic review and meta-analysis of randomised controlled trials to explore a potential association between JAKi and MTX combination and malignancies in patients with RA.

Access original article via Pubmed

Upload date: July 2021

Article image